DBV Technologies is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with food allergies and other immunological diseases. Founded by pediatricians, DBV is advancing innovative epicutaneous immunotherapy (EPIT) through its proprietary VIASKIN® patch technology, designed to re-educate the immune system by delivering small amounts of allergen through the skin. With a robust clinical development program, DBV is pursuing potential new treatment options for peanut allergy and other unmet medical needs.